Mersana Historical Income Statement
| MRSN Stock | USD 2.19 0.02 0.92% |
Historical analysis of Mersana Therapeutics income statement accounts such as Selling General Administrative of 62.5 M can show how well Mersana Therapeutics performed in making a profits. Evaluating Mersana Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Mersana Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Mersana Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mersana Therapeutics is a good buy for the upcoming year.
Mersana |
About Mersana Income Statement Analysis
Mersana Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Mersana Therapeutics shareholders. The income statement also shows Mersana investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Mersana Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Mersana Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Mersana Therapeutics. It is also known as Mersana Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Mersana Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Mersana Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.At this time, Mersana Therapeutics' Interest Income is very stable compared to the past year. As of the 28th of November 2024, Interest Expense is likely to grow to about 4.3 M, while Depreciation And Amortization is likely to drop about 1.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 855K | 927K | 1.5M | 1.1M | Interest Income | 65K | 2.9M | 11.0M | 11.6M |
Mersana Therapeutics income statement Correlations
Click cells to compare fundamentals
Mersana Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mersana Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 2.2M | 424K | 65K | 2.9M | 11.0M | 11.6M | |
| Depreciation And Amortization | 1.2M | 1.0M | 855K | 927K | 1.5M | 1.1M | |
| Interest Expense | 234K | 359K | 1.3M | 3.3M | 4.1M | 4.3M | |
| Selling General Administrative | 17.3M | 21.9M | 36.9M | 57.0M | 59.5M | 62.5M | |
| Total Revenue | 42.1M | 828K | 43K | 26.6M | 36.9M | 20.8M | |
| Gross Profit | (12.9M) | (66.2M) | (132.0M) | 25.7M | (111.4M) | (105.8M) | |
| Other Operating Expenses | 72.3M | 88.9M | 168.9M | 230.3M | 207.8M | 118.2M | |
| Operating Income | (29.2M) | (87.7M) | (169.7M) | (204.7M) | (171.0M) | (162.4M) | |
| Net Income From Continuing Ops | (28.2M) | (88.0M) | (170.1M) | (204.2M) | (197.1M) | (187.2M) | |
| Ebit | (29.2M) | (87.7M) | (168.8M) | (200.9M) | (167.6M) | (159.2M) | |
| Research Development | 55.0M | 67.0M | 132.0M | 173.4M | 148.3M | 89.9M | |
| Ebitda | (28.0M) | (86.7M) | (167.9M) | (200.0M) | (166.1M) | (157.8M) | |
| Cost Of Revenue | 55.0M | 67.0M | 132.0M | 927K | 148.3M | 155.7M | |
| Total Operating Expenses | 72.3M | 88.9M | 168.9M | 230.3M | 36.9M | 35.0M | |
| Income Before Tax | (28.2M) | (88.0M) | (170.1M) | (204.2M) | (171.7M) | (163.1M) | |
| Total Other Income Expense Net | 1.0M | 65K | (1.2M) | (445K) | (713K) | (677.4K) | |
| Net Income Applicable To Common Shares | (28.2M) | (88.0M) | (170.1M) | (204.2M) | (183.8M) | (174.6M) | |
| Net Income | (27.2M) | (88.4M) | (169.2M) | (207.5M) | (171.7M) | (163.1M) | |
| Income Tax Expense | (1.0M) | 359K | (855K) | 3.3M | 1.3M | 1.4M | |
| Net Interest Income | 2.0M | 65K | (1.2M) | (445K) | 7.0M | 7.4M | |
| Reconciled Depreciation | 1.2M | 1.0M | 855K | 927K | 1.4M | 1.2M |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
| 0.64 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Mersana Stock
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.61 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.61 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.6 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.6 | PIRS | Pieris Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.